Author

Bardees M. Foda

National Research CentreORCID 0000-0001-8869-3697Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2

Frequent Co-Authors

Richard R. NeubigiD· 2 shared Annika E. Baker· 1 shared Kathleen A. GalloiD· 1 shared Łukasz JoachimiakiD· 1 shared Marzena MazuriD· 1 shared Sean A. MisekiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Richard R. NeubigORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyFrontiers in PharmacologyPeer-reviewedJan 23, 2025

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirin

Bardees M. Foda, Annika E. Baker, Łukasz Joachimiak…·Richard R. Neubig

This study shows that CCG-257081 overcomes melanoma resistance by inducing apoptosis and inhibiting the Rho/MRTF pathway, with pirin playing a role in this process.

4 citations

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyInternational Journal of CancerPeer-reviewedJun 19, 2024

Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade

Bardees M. Foda, Sean A. Misek, Kathleen A. Gallo, Richard R. Neubig

This study shows that inhibiting the Rho/MRTF pathway with CCG-257081 enhances the effectiveness of PD1/PDL1 blockade in BRAF-resistant melanoma.

4 citations

mouseexperimental assay

𝕏 PostBluesky